Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Losartan for Prevention of Radiation-Induced Heart Failure in Breast Cancer
NCT05607017Phase 1Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Sep 2023
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of losartan in myocardial fibrosis and radiation-induced fibrosis (RIF), sponsored by Massachusetts General Hospital. Primary endpoint: Extracellular Volume of Myocardial Fibrosis at 6 months. Started Sep 2023; status: completed.
02
Drugs
losartan
03
Conditions
myocardial fibrosisradiation-induced fibrosis (RIF)
Beyond the preview
Go deeper on NCT05607017.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05607017.